Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy

Physiological Reports

Volumn 2, Issue 11, 2014, Pages

  Thallas Bonke, Vicki ^a,b   Jha, Jay C ^a,c   Gray, Stephen P ^a   Barit, David ^a   Haller, Hermann ^d   Schmidt, Harald H H W ^e   Coughlan, Melinda T ^a,c   Cooper, Mark E ^a,c   Forbes, Josephine M ^a,c,f   Jandeleit Dahm, Karin A M ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Diabetic nephropathy; NADPH oxidase; Protein kinase C; Reactive oxygen species

Indexed keywords

8 ISOPROSTANE; ALBUMIN; CREATININE; CYSTATIN C; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; NEPHRIN; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE DELETION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY INJURY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PLETHYSMOGRAPHY; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE;

EID: 85003726485     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12192     Document Type: Article

References (44)

1. Asaba, K., A. Tojo, M. L. Onozato, A. Goto, M. T. Quinn, T. Fujita, et al. 2005. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int. 67:1890-1898.
2. Babelova, A., D. Avaniadi, O. Jung, C. Fork, J. Beckmann, J. Kosowski, et al. 2012. Role of Nox4 in murine models of kidney disease. Free Radic. Biol. Med. 53:842-853.
3. Balakumar, P., M. K. Arora, S. S. Ganti, J. Reddy, and M. Singh. 2009. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol. Res. 60:24-32.
4. Baynes, J. W., and S. R. Thorpe. 1999. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9.
5. Bedard, K., and K. H. Krause. 2007. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87:245-313.
6. Block, K., Y. Gorin, and H. E. Abboud. 2009. Subcellular localization of Nox4 and regulation in diabetes. Proc Natl Acad Sci U S A 106:14385-14390.
7. Brownlee, M. 2005. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625.
8. Brownlee, M., A. Cerami, and H. Vlassara. 1988. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. The New England journal of medicine 318:1315-1321.
9. Cefalu, W. T., Z. Q. Wang, A. Bell-Farrow, F. D. Kiger, and C. Izlar. 1994. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin. Chem. 40:1317-1321.
10. Coughlan, M. T., M. E. Cooper, and J. M. Forbes. 2007a. Renal microvascular injury in diabetes: RAGE and redox signaling. Antioxid. Redox Signal. 9:331-342.
11. Coughlan, M. T., V. Thallas-Bonke, J. Pete, D. M. Long, A. Gasser, D. C. Tong, et al. 2007b. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 148: 886-895.
12. Coughlan, M. T., D. R. Thorburn, S. A. Penfold, A. Laskowski, B. E. Harcourt, K. C. Sourris, et al. 2009. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 20:742-752.
13. Dharnidharka, V. R., C. Kwon, and G. Stevens. 2002. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 40: 221-226.
14. Droge, W. 2002. Free radicals in the physiological control of cell function. Physiol. Rev. 82:47-95.
15. Duchen, M. R. 2004. Roles of mitochondria in health and disease. Diabetes 53(Suppl. 1):S96-S102.
16. Forbes, J. M., L. T. Yee, V. Thallas, M. Lassila, R. Candido, K. A. Jandeleit-Dahm, et al. 2004. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53:1813-1823.
17. Forbes, J. M., M. T. Coughlan, and M. E. Cooper. 2008. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446-1454.
18. Gill, P. S., and C. S. Wilcox. 2006. NADPH oxidases in the kidney. Antioxid. Redox Signal. 8:1597-1607.
19. Giorgi, C., C. Agnoletto, C. Baldini, A. Bononi, M. Bonora, S. Marchi, et al. 2010. Redox control of protein kinase C: cell-and disease-specific aspects. Antioxid. Redox Signal. 13:1051-1085.
20. Gorin, Y., and K. Block. 2013. Nox as a target for diabetic complications. Clin. Sci. (Lond.) 125:361-382.
21. Gorin, Y., K. Block, J. Hernandez, B. Bhandari, B. Wagner, J. L. Barnes, et al. 2005. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J. Biol. Chem. 280:39616-39626.
22. Holterman, C. E., J. F. Thibodeau, C. Towaij, A. Gutsol, A. C. Montezano, R. J. Parks, et al. 2013. Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J. Am. Soc. Nephrol. 25:784-797.
23. Jha, J. C., S. P. Gray, D. Barit, J. Okabe, A. El-Osta, T. Namikoshi, et al. 2014. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. Journal of the American Society of Nephrology: JASN 25:1237-1254.
24. Kiritoshi, S., T. Nishikawa, K. Sonoda, D. Kukidome, T. Senokuchi, T. Matsuo, et al. 2003. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 52:2570-2577.
25. Kleinschnitz, C., H. Grund, K. Wingler, M. E. Armitage, E. Jones, M. Mittal, et al. 2010. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol. 8:e1000479.
26. Krege, J. H., J. B. Hodgin, J. R. Hagaman, and O. Smithies. 1995. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115.
27. Lee, T. S., K. A. Saltsman, H. Ohashi, and G. L. King. 1989. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A 86:5141-5145.
28. Meier, M., J. K. Park, D. Overheu, T. Kirsch, C. Lindschau, F. Gueler, et al. 2007. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes 56:346-354.
29. Menne, J., M. Meier, J. K. Park, M. Boehne, T. Kirsch, C. Lindschau, et al. 2006. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int. 70:1456-1462.
30. Menne, J., N. Shushakova, J. Bartels, Y. Kiyan, R. Laudeley, H. Haller, et al. 2013. Dual Inhibition of classical protein kinase C-alpha and protein kinase C-beta isoforms protects against experimental murine diabetic nephropathy. Diabetes 62:1167-1174.
31. Nishikawa, T., D. Edelstein, X. L. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, et al. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790.
32. Ohshiro, Y., R. C. Ma, Y. Yasuda, J. Hiraoka-Yamamoto, A. C. Clermont, K. Isshiki, et al. 2006. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 55:3112-3120.
33. Sedeek, M., G. Callera, A. Montezano, A. Gutsol, F. Heitz, C. Szyndralewiez, et al. 2010. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 299:F1348-1358.
34. Shaw, J. E., R. A. Sicree, and P. Z. Zimmet. 2010. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87:4-14.
35. Sung, S. H., F. N. Ziyadeh, A. Wang, P. E. Pyagay, Y. S. Kanwar, and S. Chen. 2006. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. Journal of the American Society of Nephrology: JASN 17:3093-3104.
36. Tan, A. L., K. C. Sourris, B. E. Harcourt, V. Thallas-Bonke, S. Penfold, S. Andrikopoulos, et al. 2009. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 298:F763-770.
37. Thallas-Bonke, V., S. R. Thorpe, M. T. Coughlan, K. Fukami, F. Y. Yap, K. C. Sourris, et al. 2008. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57:460-469.
38. Thallas-Bonke, V., M. T. Coughlan, L. A. Bach, M. E. Cooper, and J. M. Forbes. 2010. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy. Am. J. Nephrol. 32:73-82.
39. Thallas-Bonke, V., M. T. Coughlan, A. L. Tan, B. E. Harcourt, P. E. Morgan, M. J. Davies, et al. 2013. Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. Nephrology 18:47-56.
40. Wendt, M. C., A. Daiber, A. L. Kleschyov, A. Mulsch, K. Sydow, E. Schulz, et al. 2005. Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4. Free Radic. Biol. Med. 39:381-391.
41. Xia, L., H. Wang, H. J. Goldberg, S. Munk, I. G. Fantus, and C. I. Whiteside. 2006. Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression. Am. J. Physiol. Renal. Physiol. 290:F345-356.
42. Yabe-Nishimura, C. 1998. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. 50:21-33.
43. Ziyadeh, F. N., and G. Wolf. 2008. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabetes Rev. 4:39-45.
44. Zou, A. P., N. Li, and A. W. Jr Cowley. 2001. Production and actions of superoxide in the renal medulla. Hypertension 37:547-553.